[
    {
        "trial_id": "NCT02008357",
        "brief_title": "Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss",
        "official_title": "Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)",
        "lillyAlias": [
            "H8A-MC-LZAZ"
        ],
        "brief_summary": "The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease \\[AD\\]).",
        "trial_status": "COMPLETED",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Cognition Disorders"
        ],
        "drugs_list": [
            "Placebo",
            "Solanezumab"
        ],
        "enrollment": 1169,
        "inclusion_criteria": "inclusion criteria: \n\n Has a Mini-Mental State Examination (MMSE) score at screening of 25 to 30\n Has a global Clinical Dementia Rating (CDR) scale score at screening of 0\n Has a Logical Memory II score at screening of 6 to 18\n Has a florbetapir positron emission tomography (PET) scan that shows evidence of brain amyloid pathology at screening\n Has a study partner that is willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or electronic communication)",
        "exclusion_criteria": "exclusion criteria: \n\nIs receiving a prescription acetylcholinesterase inhibitor (AChEI) and/or memantine at screening or baseline\nLacks good venous access, such that intravenous drug delivery or multiple blood draws would be precluded\nHas current serious or unstable illness including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease or other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study\nHas had a history within the last 5 years of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma resulting in protracted loss of consciousness\nHas had a history within the last 5 years of a primary or recurrent malignant disease with the exception of any in situ cancer that was appropriately treated and is being appropriately monitored, such as resected cutaneous squamous cell carcinoma in situ or in situ prostate cancer with normal prostate-specific antigen post-treatment\nHas a known history of human immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis)\nIs clinically judged by the investigator to be at serious risk for suicide\nHas a history within the past 2 years of major depression or bipolar disorder as defined by the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM)\nHas a history within the past 5 years of chronic alcohol or drug abuse/dependence as defined by the most current version of the DSM\n\nOpen-Label Inclusion Criteria:\n\nAll participants who complete the placebo-controlled period will be allowed to continue into the open-label period",
        "keywords": [
            "Cognition",
            "Prevention"
        ]
    },
    {
        "trial_id": "NCT01900665",
        "brief_title": "Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo",
        "official_title": "Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo",
        "lillyAlias": [
            "H8A-MC-LZAX"
        ],
        "brief_summary": "To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.",
        "trial_status": "TERMINATED",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Alzheimer's Disease"
        ],
        "drugs_list": [
            "Solanezumab",
            "Placebo"
        ],
        "enrollment": 2129,
        "inclusion_criteria": "inclusion criteria: \n\n Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable AD\n Has a Modified Hachinski Ischemia Scale score of less than or equal to 4\n Has a Mini-Mental State Examination (MMSE) score of 20 through 26 at Screening visit\n Has a Geriatric Depression Scale score of less than or equal to 6 (on the staff-administered short form)\n Has had a magnetic resonance imaging (MRI) or computerized tomography (CT) scan performed within the past 2 years that has confirmed no findings inconsistent with a diagnosis of AD\n Has a florbetapir positron emission tomography (PET) scan or cerebrospinal fluid (CSF) result consistent with the presence of amyloid pathology at screening",
        "exclusion_criteria": "exclusion criteria: \n\nDoes not have a reliable caregiver who is in frequent contact with the participant (defined as at least 10 hours per week), will accompany the participant to the office and/or be available by telephone at designated times, and will monitor administration of prescribed medications\nMeets National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS/AIREN) criteria for vascular dementia\nHas current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study; or has a life expectancy of \\<2 years\nHas had a history within the last 5 years of a serious infectious disease affecting the brain or head trauma resulting in protracted loss of consciousness\nHas a history within the last 5 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal prostate-specific antigen posttreatment\nHas a known history of human immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions\nHas received acetylcholinesterase inhibitor (AChEIs), memantine and/or other AD therapy for less than 4 months or has less than 2 months of stable therapy on these treatments\nHas received medications that affect the central nervous system (CNS), except treatments for AD, for less than 4 weeks\nHas a history of chronic alcohol or drug abuse/dependence within the past 5 years\nHas a Visit 1 MRI with results showing \\>4 Amyloid-related Imaging Abnormality (ARIA), -hemorrhage /hemosiderin deposition (ARIA-H) or presence of ARIA-E (edema/effusions)",
        "keywords": []
    }
]